Cabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia Gravis
By Colin Kellaher
Cabaletta Bio has won Food and Drug Administration authorization to launch a Phase 1/2 study of its CABA-201 investigational therapy in patients with the rare autoimmune disease generalized myasthenia gravis.
The Philadelphia clinical-stage biotechnology company on Monday said the green light expands the clinical development of its lead product candidate beyond rheumatology into neurology, adding that it plans to initiate a study across two parallel patient cohorts based on autoantibody status.
Cabaletta--which previously received FDA approvals to study CABA-201 in lupus, myositis and systemic sclerosis--said it is on track to deliver initial clinical data from patients with lupus and/or myositis in the first half of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 06, 2023 07:40 ET (12:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying